Celgene paid top dollar for Juno Therapeutics last month, but the biotech heavyweight may end up with buyer's remorse. Here's why.
News & Analysis: Juno Therapeutics
Right product, right price, right time. What more can you ask for?
Find out which of these companies was involved in a merger.
The rumor turned out to be true.
Celgene appears to have lit a fire beneath all three of these small biotech stocks.
Celgene may be considering a multibillion-dollar bid to acquire Juno.
Stocks had a huge day, sending the major indexes to new records. Shares of Juno Therapeutics soared following a buyout report, and Ford slumped on disappointing guidance.
The pharmaceutical industry's long-anticipated consolidation of CAR-T biotech companies may be starting.
Juno's year-long rally came to an abrupt halt last month on concerns that it won't be able to catch up to the leaders in CAR-T.
The biotech pushed past the loss of its lead drug to show its next-generation drug could fill the void.